Must Reads In Genitourinary Cancer
Genitourinary Cancer for March/April 2019
Genitourinary Cancer for January/February 2019
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Obesity-related cancers such as kidney cancer rising among young adults, Sung H et al. Lancet Public Health. 2019 Feb 4.
Genitourinary Cancer for September/October 2018
Genitourinary Cancer for July/August 2018
Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10
Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.
Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002
Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma.
Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030
Genitourinary Cancer for May/June 2018
Access to care linked to better outcomes in black men with prostate cancer, Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.
Statins may affect prostate cancer microenvironment, Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.
Prostate cancer risks higher in smokers, Foerster B et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1071.
Prostate cancer: Docetaxel prednisone response better in black men, Halabi et al, George et al. ASCO 2018 Abstracts LBA5005 and LBA5009.